Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Immunicum AB: Invitation to Investor Events


Posted on: 21 Mar 18

Press Release

21 March 2018

Immunicum AB: Invitation to Investor Events

Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, announced today that the Company will host two investor events in April. At both events, Carlos de Sousa, CEO of Immunicum, will give the current corporate presentation and he and other members of the Immunicum leadership team will be available for a question and answer session.   

Stockholm
Date: Wednesday, April 11, 2018
Time: 18:00 - 20:00 CET
Location: Citykonferensen Ingenjörshuset
                 Room: Styrelserummet
                 Malmskillnadsgatan 46
                 111 84 Stockholm

Gothenburg
Date: Wednesday, April 18, 2018
Time: 18:00 - 20:00 CET
Location:  First Hotel G
                  Restaurant Orkidé
                  Nils Ericsonplatsen 4
                  411 03 Gothenburg

To register to attend the events,  please send an email to events@immunicum.com with your full name and the selected location (Stockholm or Gothenburg).

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com

Michaela Gertz, CFO, Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com  

Media Relations

Gretchen Schweitzer and Joanne Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com

About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.  www.immunicum.com

Attachment:

http://www.globenewswire.com/NewsRoom/AttachmentNg/6ce617ce-ef9d-4f09-a0e8-6fdd8b89295e

GlobeNewswire
globenewswire.com

Last updated on: 22/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.